Review



antibody against γh2ax  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Cell Signaling Technology Inc antibody against γh2ax
    CRC cells with JAML overexpression demonstrate increased apoptosis and DNA damage after irradiation, accompanied by inhibiting the ATR-CHK1 signaling pathway. (A) Representative images of apoptosis of LOVO and DLD-1 cells using flow cytometry after 24 h after X-ray irradiation. (B and C) Quantitative statistics of apoptosis of LOVO and DLD-1 cells. (D) Representative images of fluorescence of <t>γH2AX</t> in LOVO and DLD-1 cells after 12 h of X-ray irradiation or lack of X-ray irradiation. (E and F) Quantitative statistical analysis of the γH2AX-positive rate in LOVO and DLD-1 cells. (G and L) Western blot images of the ATR-CHK1 signaling pathway’s protein expression in LOVO and DLD-1 cells after 24 h of X-ray irradiation/lack of irradiation. (H–K and M−P) Quantitative statistical analysis of the relative ATR-CHK1 signaling pathway’s protein expression in LOVO and DLD-1 cells (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001).
    Antibody Against γh2ax, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibody against γh2ax/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    antibody against γh2ax - by Bioz Stars, 2026-04
    90/100 stars

    Images

    1) Product Images from "Overexpression of JAML in colorectal cancer cells predicts higher radiosensitivity by inactivating ATR pathway"

    Article Title: Overexpression of JAML in colorectal cancer cells predicts higher radiosensitivity by inactivating ATR pathway

    Journal: Clinical and Translational Radiation Oncology

    doi: 10.1016/j.ctro.2025.101016

    CRC cells with JAML overexpression demonstrate increased apoptosis and DNA damage after irradiation, accompanied by inhibiting the ATR-CHK1 signaling pathway. (A) Representative images of apoptosis of LOVO and DLD-1 cells using flow cytometry after 24 h after X-ray irradiation. (B and C) Quantitative statistics of apoptosis of LOVO and DLD-1 cells. (D) Representative images of fluorescence of γH2AX in LOVO and DLD-1 cells after 12 h of X-ray irradiation or lack of X-ray irradiation. (E and F) Quantitative statistical analysis of the γH2AX-positive rate in LOVO and DLD-1 cells. (G and L) Western blot images of the ATR-CHK1 signaling pathway’s protein expression in LOVO and DLD-1 cells after 24 h of X-ray irradiation/lack of irradiation. (H–K and M−P) Quantitative statistical analysis of the relative ATR-CHK1 signaling pathway’s protein expression in LOVO and DLD-1 cells (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001).
    Figure Legend Snippet: CRC cells with JAML overexpression demonstrate increased apoptosis and DNA damage after irradiation, accompanied by inhibiting the ATR-CHK1 signaling pathway. (A) Representative images of apoptosis of LOVO and DLD-1 cells using flow cytometry after 24 h after X-ray irradiation. (B and C) Quantitative statistics of apoptosis of LOVO and DLD-1 cells. (D) Representative images of fluorescence of γH2AX in LOVO and DLD-1 cells after 12 h of X-ray irradiation or lack of X-ray irradiation. (E and F) Quantitative statistical analysis of the γH2AX-positive rate in LOVO and DLD-1 cells. (G and L) Western blot images of the ATR-CHK1 signaling pathway’s protein expression in LOVO and DLD-1 cells after 24 h of X-ray irradiation/lack of irradiation. (H–K and M−P) Quantitative statistical analysis of the relative ATR-CHK1 signaling pathway’s protein expression in LOVO and DLD-1 cells (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001).

    Techniques Used: Over Expression, Irradiation, Flow Cytometry, Fluorescence, Western Blot, Protein-Protein interactions, Expressing

    LOVO cells with JAML overexpression demonstrate increased apoptosis and DNA damage after irradiation. (A)Representative image and (B) protein quantitative analysis of Western blot analysis of JAML in lentivirus-overexpression-transfected LOVO cells. (C) mRNA expression levels of JAML in lentivirus-overexpression-transfected LOVO cells. (D) Representative images and (E) survival curve of plate cloning of JAML overexpressed in LOVO cells after X-ray (8 Gy) irradiation. (F) Representative images and (G) quantitative analysis of cellular immunofluorescence of γH2AX (red light) of JAML overexpressed in LOVO cells after X-ray (8 Gy) irradiating 12 h. (H) Representative images and (I) quantitative analysis of flow cytometry apoptosis of JAML overexpressed in LOVO cells after X-ray (8 Gy) irradiating 24 h. (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
    Figure Legend Snippet: LOVO cells with JAML overexpression demonstrate increased apoptosis and DNA damage after irradiation. (A)Representative image and (B) protein quantitative analysis of Western blot analysis of JAML in lentivirus-overexpression-transfected LOVO cells. (C) mRNA expression levels of JAML in lentivirus-overexpression-transfected LOVO cells. (D) Representative images and (E) survival curve of plate cloning of JAML overexpressed in LOVO cells after X-ray (8 Gy) irradiation. (F) Representative images and (G) quantitative analysis of cellular immunofluorescence of γH2AX (red light) of JAML overexpressed in LOVO cells after X-ray (8 Gy) irradiating 12 h. (H) Representative images and (I) quantitative analysis of flow cytometry apoptosis of JAML overexpressed in LOVO cells after X-ray (8 Gy) irradiating 24 h. (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Techniques Used: Over Expression, Irradiation, Western Blot, Transfection, Expressing, Cloning, Immunofluorescence, Flow Cytometry



    Similar Products

    95
    Miltenyi Biotec anti γh2ax ps139 fitc
    Anti γh2ax Ps139 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti γh2ax ps139 fitc/product/Miltenyi Biotec
    Average 95 stars, based on 1 article reviews
    anti γh2ax ps139 fitc - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    94
    Sino Biological t62 sinobiologicals ab 3064900 rabbit γh2ax
    T62 Sinobiologicals Ab 3064900 Rabbit γh2ax, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/t62 sinobiologicals ab 3064900 rabbit γh2ax/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    t62 sinobiologicals ab 3064900 rabbit γh2ax - by Bioz Stars, 2026-04
    94/100 stars
      Buy from Supplier

    96
    Proteintech phosphorylated histone h2ax γh2ax
    Combination synergy on DNA damage, NHEJ repair, and apoptosis. (A, B) Western blotting and quantification analyses of FASN, PARP1, <t>γ-H2AX,</t> and actin loading control in MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (C, D) The fraction of maximum γ-H2AX induction derived using the Bliss-compatible scaling formula. (E) Host cell reactivation assay of NHEJ activity in MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (F) Comparison between the observed and expected NHEJ activity inhibition by the combination using the Bliss independence model. (G) Caspasae3/7 activity assay of MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (H) The fraction of maximum caspase 3/7 activation derived using the Bliss-compatible scaling formula. (I) Annexin V staining as an indicator of apoptosis in MDA-MB-231 and MDA-MB-436 cells following treatments with 5HLS, talazoparib, or the combination. (J) The fraction of maximum apoptosis induction derived using the Bliss-compatible scaling formula. n = 3; ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001.
    Phosphorylated Histone H2ax γh2ax, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated histone h2ax γh2ax/product/Proteintech
    Average 96 stars, based on 1 article reviews
    phosphorylated histone h2ax γh2ax - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    96
    Proteintech phospho histone h2ax γh2ax
    Combination synergy on DNA damage, NHEJ repair, and apoptosis. (A, B) Western blotting and quantification analyses of FASN, PARP1, <t>γ-H2AX,</t> and actin loading control in MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (C, D) The fraction of maximum γ-H2AX induction derived using the Bliss-compatible scaling formula. (E) Host cell reactivation assay of NHEJ activity in MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (F) Comparison between the observed and expected NHEJ activity inhibition by the combination using the Bliss independence model. (G) Caspasae3/7 activity assay of MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (H) The fraction of maximum caspase 3/7 activation derived using the Bliss-compatible scaling formula. (I) Annexin V staining as an indicator of apoptosis in MDA-MB-231 and MDA-MB-436 cells following treatments with 5HLS, talazoparib, or the combination. (J) The fraction of maximum apoptosis induction derived using the Bliss-compatible scaling formula. n = 3; ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001.
    Phospho Histone H2ax γh2ax, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho histone h2ax γh2ax/product/Proteintech
    Average 96 stars, based on 1 article reviews
    phospho histone h2ax γh2ax - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    96
    Proteintech anti γh2ax
    Combination synergy on DNA damage, NHEJ repair, and apoptosis. (A, B) Western blotting and quantification analyses of FASN, PARP1, <t>γ-H2AX,</t> and actin loading control in MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (C, D) The fraction of maximum γ-H2AX induction derived using the Bliss-compatible scaling formula. (E) Host cell reactivation assay of NHEJ activity in MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (F) Comparison between the observed and expected NHEJ activity inhibition by the combination using the Bliss independence model. (G) Caspasae3/7 activity assay of MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (H) The fraction of maximum caspase 3/7 activation derived using the Bliss-compatible scaling formula. (I) Annexin V staining as an indicator of apoptosis in MDA-MB-231 and MDA-MB-436 cells following treatments with 5HLS, talazoparib, or the combination. (J) The fraction of maximum apoptosis induction derived using the Bliss-compatible scaling formula. n = 3; ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001.
    Anti γh2ax, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti γh2ax/product/Proteintech
    Average 96 stars, based on 1 article reviews
    anti γh2ax - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    95
    Bethyl γh2ax
    Combination synergy on DNA damage, NHEJ repair, and apoptosis. (A, B) Western blotting and quantification analyses of FASN, PARP1, <t>γ-H2AX,</t> and actin loading control in MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (C, D) The fraction of maximum γ-H2AX induction derived using the Bliss-compatible scaling formula. (E) Host cell reactivation assay of NHEJ activity in MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (F) Comparison between the observed and expected NHEJ activity inhibition by the combination using the Bliss independence model. (G) Caspasae3/7 activity assay of MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (H) The fraction of maximum caspase 3/7 activation derived using the Bliss-compatible scaling formula. (I) Annexin V staining as an indicator of apoptosis in MDA-MB-231 and MDA-MB-436 cells following treatments with 5HLS, talazoparib, or the combination. (J) The fraction of maximum apoptosis induction derived using the Bliss-compatible scaling formula. n = 3; ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001.
    γh2ax, supplied by Bethyl, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/γh2ax/product/Bethyl
    Average 95 stars, based on 1 article reviews
    γh2ax - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    90
    Cell Signaling Technology Inc antibody against γh2ax
    CRC cells with JAML overexpression demonstrate increased apoptosis and DNA damage after irradiation, accompanied by inhibiting the ATR-CHK1 signaling pathway. (A) Representative images of apoptosis of LOVO and DLD-1 cells using flow cytometry after 24 h after X-ray irradiation. (B and C) Quantitative statistics of apoptosis of LOVO and DLD-1 cells. (D) Representative images of fluorescence of <t>γH2AX</t> in LOVO and DLD-1 cells after 12 h of X-ray irradiation or lack of X-ray irradiation. (E and F) Quantitative statistical analysis of the γH2AX-positive rate in LOVO and DLD-1 cells. (G and L) Western blot images of the ATR-CHK1 signaling pathway’s protein expression in LOVO and DLD-1 cells after 24 h of X-ray irradiation/lack of irradiation. (H–K and M−P) Quantitative statistical analysis of the relative ATR-CHK1 signaling pathway’s protein expression in LOVO and DLD-1 cells (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001).
    Antibody Against γh2ax, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibody against γh2ax/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    antibody against γh2ax - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    Image Search Results


    Combination synergy on DNA damage, NHEJ repair, and apoptosis. (A, B) Western blotting and quantification analyses of FASN, PARP1, γ-H2AX, and actin loading control in MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (C, D) The fraction of maximum γ-H2AX induction derived using the Bliss-compatible scaling formula. (E) Host cell reactivation assay of NHEJ activity in MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (F) Comparison between the observed and expected NHEJ activity inhibition by the combination using the Bliss independence model. (G) Caspasae3/7 activity assay of MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (H) The fraction of maximum caspase 3/7 activation derived using the Bliss-compatible scaling formula. (I) Annexin V staining as an indicator of apoptosis in MDA-MB-231 and MDA-MB-436 cells following treatments with 5HLS, talazoparib, or the combination. (J) The fraction of maximum apoptosis induction derived using the Bliss-compatible scaling formula. n = 3; ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001.

    Journal: Genes & Diseases

    Article Title: Targeting fatty acid synthase to overcome PARP inhibitor resistance and to create an artificial synthetic lethality for triple-negative breast cancer

    doi: 10.1016/j.gendis.2025.101817

    Figure Lengend Snippet: Combination synergy on DNA damage, NHEJ repair, and apoptosis. (A, B) Western blotting and quantification analyses of FASN, PARP1, γ-H2AX, and actin loading control in MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (C, D) The fraction of maximum γ-H2AX induction derived using the Bliss-compatible scaling formula. (E) Host cell reactivation assay of NHEJ activity in MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (F) Comparison between the observed and expected NHEJ activity inhibition by the combination using the Bliss independence model. (G) Caspasae3/7 activity assay of MDA-MB-231 and MDA-MB-436 cells treated with 5HLS, talazoparib, or the combination. (H) The fraction of maximum caspase 3/7 activation derived using the Bliss-compatible scaling formula. (I) Annexin V staining as an indicator of apoptosis in MDA-MB-231 and MDA-MB-436 cells following treatments with 5HLS, talazoparib, or the combination. (J) The fraction of maximum apoptosis induction derived using the Bliss-compatible scaling formula. n = 3; ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001.

    Article Snippet: Antibodies against PARP1 (#66520) and phosphorylated histone H2AX (γH2AX) (#613402) were from Proteintech (Rosemont, Illinois, USA) and BioLegend (San Diego, California, USA), respectively.

    Techniques: Western Blot, Control, Derivative Assay, Host-Cell Reactivation, Activity Assay, Comparison, Inhibition, Activation Assay, Staining

    In - vivo effect of 5HLS and talazoparib combination on tumor growth. (A) Tumor volume and body weight of mice treated by vehicle (Veh), 5HLS, talazoparib (Tal), or combination (Comb) of 5HLS and talazoparib. (B, C) Gross anatomy (B) and wet weight (C) of dissected xenograft tumors at the end of the study. (D) Synergy analysis. Tumor growth inhibition (TGI) was derived using the wet weight of tumors. The expected combination inhibition (C (E) ) was calculated from that of 5HLS and talazoparib alone using the Bliss independence model (see Materials and Methods ). C (O) represents the observed combination inhibition. (E) Immunohistochemical analyses of FASN, PARP, and γH2AX. Scale bar, 50 μm. (F) Western blotting analyses of FASN, BRCA1, PARP1, cleaved PARP1 (cPARP1), γH2AX, and actin loading control in xenograft tumors from mice treated with vehicle, 5HLS, talazoparib, and the combination of 5HLS and talazoparib. Each lane represents mixed samples of five tumors in equal proportion within the treatment group. n = 5; ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001.

    Journal: Genes & Diseases

    Article Title: Targeting fatty acid synthase to overcome PARP inhibitor resistance and to create an artificial synthetic lethality for triple-negative breast cancer

    doi: 10.1016/j.gendis.2025.101817

    Figure Lengend Snippet: In - vivo effect of 5HLS and talazoparib combination on tumor growth. (A) Tumor volume and body weight of mice treated by vehicle (Veh), 5HLS, talazoparib (Tal), or combination (Comb) of 5HLS and talazoparib. (B, C) Gross anatomy (B) and wet weight (C) of dissected xenograft tumors at the end of the study. (D) Synergy analysis. Tumor growth inhibition (TGI) was derived using the wet weight of tumors. The expected combination inhibition (C (E) ) was calculated from that of 5HLS and talazoparib alone using the Bliss independence model (see Materials and Methods ). C (O) represents the observed combination inhibition. (E) Immunohistochemical analyses of FASN, PARP, and γH2AX. Scale bar, 50 μm. (F) Western blotting analyses of FASN, BRCA1, PARP1, cleaved PARP1 (cPARP1), γH2AX, and actin loading control in xenograft tumors from mice treated with vehicle, 5HLS, talazoparib, and the combination of 5HLS and talazoparib. Each lane represents mixed samples of five tumors in equal proportion within the treatment group. n = 5; ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001.

    Article Snippet: Antibodies against PARP1 (#66520) and phosphorylated histone H2AX (γH2AX) (#613402) were from Proteintech (Rosemont, Illinois, USA) and BioLegend (San Diego, California, USA), respectively.

    Techniques: In Vivo, Inhibition, Derivative Assay, Immunohistochemical staining, Western Blot, Control

    CRC cells with JAML overexpression demonstrate increased apoptosis and DNA damage after irradiation, accompanied by inhibiting the ATR-CHK1 signaling pathway. (A) Representative images of apoptosis of LOVO and DLD-1 cells using flow cytometry after 24 h after X-ray irradiation. (B and C) Quantitative statistics of apoptosis of LOVO and DLD-1 cells. (D) Representative images of fluorescence of γH2AX in LOVO and DLD-1 cells after 12 h of X-ray irradiation or lack of X-ray irradiation. (E and F) Quantitative statistical analysis of the γH2AX-positive rate in LOVO and DLD-1 cells. (G and L) Western blot images of the ATR-CHK1 signaling pathway’s protein expression in LOVO and DLD-1 cells after 24 h of X-ray irradiation/lack of irradiation. (H–K and M−P) Quantitative statistical analysis of the relative ATR-CHK1 signaling pathway’s protein expression in LOVO and DLD-1 cells (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001).

    Journal: Clinical and Translational Radiation Oncology

    Article Title: Overexpression of JAML in colorectal cancer cells predicts higher radiosensitivity by inactivating ATR pathway

    doi: 10.1016/j.ctro.2025.101016

    Figure Lengend Snippet: CRC cells with JAML overexpression demonstrate increased apoptosis and DNA damage after irradiation, accompanied by inhibiting the ATR-CHK1 signaling pathway. (A) Representative images of apoptosis of LOVO and DLD-1 cells using flow cytometry after 24 h after X-ray irradiation. (B and C) Quantitative statistics of apoptosis of LOVO and DLD-1 cells. (D) Representative images of fluorescence of γH2AX in LOVO and DLD-1 cells after 12 h of X-ray irradiation or lack of X-ray irradiation. (E and F) Quantitative statistical analysis of the γH2AX-positive rate in LOVO and DLD-1 cells. (G and L) Western blot images of the ATR-CHK1 signaling pathway’s protein expression in LOVO and DLD-1 cells after 24 h of X-ray irradiation/lack of irradiation. (H–K and M−P) Quantitative statistical analysis of the relative ATR-CHK1 signaling pathway’s protein expression in LOVO and DLD-1 cells (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001).

    Article Snippet: In brief, at 12 h after 8-Gy X-ray irradiation, the cells were cultured on 24-well chamber slides, washed with PBS, fixed with 4 % paraformaldehyde (Biosharp, China), permeabilized with 0.1 % TritonX-100 (Solarbio, China), blocked with 3 % bovine serum albumin (BSA), and incubated with an antibody against γH2AX (Cell Signaling Technology, dilution 1:200, USA) at 4 °C overnight.

    Techniques: Over Expression, Irradiation, Flow Cytometry, Fluorescence, Western Blot, Protein-Protein interactions, Expressing

    LOVO cells with JAML overexpression demonstrate increased apoptosis and DNA damage after irradiation. (A)Representative image and (B) protein quantitative analysis of Western blot analysis of JAML in lentivirus-overexpression-transfected LOVO cells. (C) mRNA expression levels of JAML in lentivirus-overexpression-transfected LOVO cells. (D) Representative images and (E) survival curve of plate cloning of JAML overexpressed in LOVO cells after X-ray (8 Gy) irradiation. (F) Representative images and (G) quantitative analysis of cellular immunofluorescence of γH2AX (red light) of JAML overexpressed in LOVO cells after X-ray (8 Gy) irradiating 12 h. (H) Representative images and (I) quantitative analysis of flow cytometry apoptosis of JAML overexpressed in LOVO cells after X-ray (8 Gy) irradiating 24 h. (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Journal: Clinical and Translational Radiation Oncology

    Article Title: Overexpression of JAML in colorectal cancer cells predicts higher radiosensitivity by inactivating ATR pathway

    doi: 10.1016/j.ctro.2025.101016

    Figure Lengend Snippet: LOVO cells with JAML overexpression demonstrate increased apoptosis and DNA damage after irradiation. (A)Representative image and (B) protein quantitative analysis of Western blot analysis of JAML in lentivirus-overexpression-transfected LOVO cells. (C) mRNA expression levels of JAML in lentivirus-overexpression-transfected LOVO cells. (D) Representative images and (E) survival curve of plate cloning of JAML overexpressed in LOVO cells after X-ray (8 Gy) irradiation. (F) Representative images and (G) quantitative analysis of cellular immunofluorescence of γH2AX (red light) of JAML overexpressed in LOVO cells after X-ray (8 Gy) irradiating 12 h. (H) Representative images and (I) quantitative analysis of flow cytometry apoptosis of JAML overexpressed in LOVO cells after X-ray (8 Gy) irradiating 24 h. (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Article Snippet: In brief, at 12 h after 8-Gy X-ray irradiation, the cells were cultured on 24-well chamber slides, washed with PBS, fixed with 4 % paraformaldehyde (Biosharp, China), permeabilized with 0.1 % TritonX-100 (Solarbio, China), blocked with 3 % bovine serum albumin (BSA), and incubated with an antibody against γH2AX (Cell Signaling Technology, dilution 1:200, USA) at 4 °C overnight.

    Techniques: Over Expression, Irradiation, Western Blot, Transfection, Expressing, Cloning, Immunofluorescence, Flow Cytometry